Inviragen and PharmaJet receive NIH grant for dengue vaccine

10/10/2010 | American City Business Journals

The NIH's National Institute of Allergy and Infectious Diseases has awarded a five-year, $15.5 million grant to Inviragen and PharmaJet to develop a needleless vaccine that can offer protection against all four strains of dengue virus. Inviragen's DENVax vaccine can be administered using PharmaJet's injector that uses pressurized liquid in drug delivery.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Information Officer
Meridian Health Plan
Detroit, MI
Actuary
NTA Life
Addison, TX
Vice President - Government Products
Health Alliance Plan
Detroit, MI